FIDIA'S HYALGAN PMA FOR OSTEOARTHRITIS PAIN RECOMMENDED FOR APPROVAL BY FDA ADVISORY PANEL; USE AFTER FAILED CONSERVATIVE THERAPY ENDORSED
This article was originally published in The Gray Sheet
Fidia Pharmaceutical's Hyalgan premarket approval application received a unanimous recommendation for approval with conditions for treating pain caused by osteoarthritis of the knee from FDA's Orthopedic and Rehabilitation Devices Panel Nov. 21 in Gaithersburg, Maryland. The panel conditioned its approval recommendation on five labeling changes.
You may also be interested in...
Anika Therapeutics is pursuing a multiple-treatment indication for its Orthovisc sodium hyaluronic-acid (HA) injectable treatment for osteoarthritis of the knee, the firm reports.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.